SparX Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$36M
- Investors
-
3
SparX General Information
Description
Developer of nanobody-based biopharmaceutical therapeutics designed for immuno-oncology research and development serving the pharmaceutical industry. The company offers antibody drug conjugate and bispecific antibody platforms, including dual-payload and biparatopic nanobody architectures with artificial intelligence-enabled discovery and in-house current good manufacturing practice production, enabling drug developers to generate and advance oncology candidates with integrated translational and clinical development capabilities.
Contact Information
Website
www.sparxbio.comCorporate Office
- 700 East Business Center Drive
- Mount Prospect, IL 60056
- United States
Corporate Office
- 700 East Business Center Drive
- Mount Prospect, IL 60056
- United States
SparX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series B) | 31-Dec-2021 | $36M | Completed | Clinical Trials - Phase 1 |
SparX Patents
SparX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021257822-A2 | Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (pd-l1) | Inactive | 18-Jun-2020 | ||
| WO-2021257822-A3 | Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (pd-l1) | Inactive | 18-Jun-2020 | ||
| US-20210188897-A1 | Neuroactive steroids and compositions and methods thereof | Inactive | 05-Dec-2019 | ||
| WO-2021113068-A1 | Neuroactive steroids and compositions and methods thereof | Inactive | 05-Dec-2019 | ||
| JP-2024159749-A | Binding molecules specific for claudin 18.2, compositions and methods thereof, for treatment of cancer and other diseases | Inactive | 28-Dec-2018 | C07K16/28 |
SparX Signals
SparX Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Highlight Capital | Venture Capital | Minority | ||
| Shenzhen Qianhai Rotating Stone Fund Management | Growth/Expansion | Minority | ||
| Shenzhen Sangel Venture Capital | Venture Capital | Minority |
SparX FAQs
-
When was SparX founded?
SparX was founded in 2018.
-
Where is SparX headquartered?
SparX is headquartered in Mount Prospect, IL.
-
What is the size of SparX?
SparX has 50 total employees.
-
What industry is SparX in?
SparX’s primary industry is Drug Discovery.
-
Is SparX a private or public company?
SparX is a Private company.
-
What is SparX’s current revenue?
The current revenue for SparX is .
-
How much funding has SparX raised over time?
SparX has raised $36M.
-
Who are SparX’s investors?
Highlight Capital, Shenzhen Qianhai Rotating Stone Fund Management, and Shenzhen Sangel Venture Capital have invested in SparX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process